CRNX Stock Overview
Crinetics Pharmaceuticals, Inc., a clinical stage pharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for rare endocrine diseases and endocrine-related tumors.
Crinetics Pharmaceuticals, Inc. Competitors
Price History & Performance
|Historical stock prices|
|Current Share Price||US$18.59|
|52 Week High||US$28.95|
|52 Week Low||US$15.91|
|1 Month Change||-4.76%|
|3 Month Change||3.28%|
|1 Year Change||-10.63%|
|3 Year Change||21.98%|
|5 Year Change||n/a|
|Change since IPO||-24.15%|
Recent News & Updates
Here's Why We're Not Too Worried About Crinetics Pharmaceuticals' (NASDAQ:CRNX) Cash Burn Situation
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
|CRNX||US Biotechs||US Market|
Return vs Industry: CRNX exceeded the US Biotechs industry which returned -30.6% over the past year.
Return vs Market: CRNX exceeded the US Market which returned -23.7% over the past year.
|CRNX Average Weekly Movement||8.3%|
|Biotechs Industry Average Movement||11.0%|
|Market Average Movement||6.9%|
|10% most volatile stocks in US Market||15.7%|
|10% least volatile stocks in US Market||2.8%|
Stable Share Price: CRNX is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 8% a week.
Volatility Over Time: CRNX's weekly volatility (8%) has been stable over the past year.
About the Company
Crinetics Pharmaceuticals, Inc., a clinical stage pharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for rare endocrine diseases and endocrine-related tumors. Its lead product candidate is Paltusotine, an oral selective nonpeptide somatostatin receptor type 2 agonist that has completed phase III clinical trial for the treatment of acromegaly, as well as completed phase II clinical trial to treat carcinoid syndrome and nonfunctional neuroendocrine tumors (NETs). The company is also developing CRN04777, an oral selective nonpeptide somatostatin type 5 receptor agonist, which is in phase I clinical trial for the treatment of congenital hyperinsulinism; and CRN04894, an oral adrenocorticotrophic hormone antagonist that is in phase I clinical trial for the treatment of Cushing's and congenital adrenal hyperplasia diseases.
Crinetics Pharmaceuticals, Inc. Fundamentals Summary
|CRNX fundamental statistics|
Is CRNX overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|CRNX income statement (TTM)|
|Cost of Revenue||US$84.26m|
Last Reported Earnings
Jun 30, 2022
Next Earnings Date
|Earnings per share (EPS)||-2.52|
|Net Profit Margin||-2,918.40%|
How did CRNX perform over the long term?See historical performance and comparison